Scientist Synthesizes New Molecule That Kills Hard-To-Treat Breast Cancer

Dr. Jung-Mo Ahn led a team of researchers in the creation of ERX-41, a new compound that uses breast cancer cells’ own weaknesses to “wipe out” tumor cells. Most existing breast cancer treatments require the presence of estrogen receptors (ERs) to work. This leaves few options for patients with triple-negative breast cancer, or TNBC, which lacks ERs and therefore is resistant to such treatments.

Meanwhile, ERX-41 is effective regardless of whether the targeted cancer cells possess ERs. It works by binding with lysosomal acid lipase A (LIPA), a protein found in the cell’s endoplasmic reticulum. (You might remember this as the maze-like cellular structure on all your middle school biology exams.) Cancer cells produce far more LIPA than necessary, but the endoplasmic reticulum usually processes them efficiently enough to keep the cells healthy. When ERX-41 binds to LIPA, however, it jams the endoplasmic reticulum and causes a buildup, which eventually bloats and kills the cell.

Dr. Ahn’s team tested ERX-41 in isolated cells and human cancer tissue, where the molecule inhibited growth without killing healthy cells. They then tested the molecule in live mice with various forms of human cancer. ERX-41 successfully reduced the size of their tumors without producing any adverse effects, such as weight fluctuation or behavioral changes. (A later test in healthy mice further solidified a lack of negative side effects.) The molecule’s effectiveness with other treatment-resistant cancers, like pancreatic cancer, ovarian cancer, and glioblastoma, led the researchers to believe ERX-41 might someday be used to treat those diseases as well.

This isn’t the first time Dr. Ahn has moved the needle in regards to beating treatment-resistant cancers. Less than five years ago he developed candidate compounds that block the co-regulators necessary for breast cancer to grow. A few years before that, Dr. Ahn synthesized another molecule capable of inhibiting the growth of prostate cancer.

Dr. Ahn and two colleagues founded EtiraRX, a Dallas therapeutics startup, in order to conduct clinical trials of each novel treatment. Patents are currently pending for ERX-41; in the meantime, the team is busy planning clinical trials for ERX-41, which will begin in early 2023.

Continue reading

Scientists Confirm the Presence of Water on the Moon

Scientists have confirmed the discovery of molecular water on the moon. Is there any of it in a form we can use? That's less clear.

Review: The Oculus Quest 2 Could Be the Tipping Point for VR Mass Adoption

The Oculus Quest 2 is now available, and it's an improvement over the original in every way that matters. And yet, it's $100 less expensive than the last release. Having spent some time with the Quest 2, I believe we might look back on it as the headset that finally made VR accessible to mainstream consumers.

SpaceX Launches ‘Better Than Nothing’ Starlink Beta

Those lucky few who have gotten invitations to try the service will have to pay a hefty up-front cost, and the speeds aren't amazing. Still, it's a new generation of satellite internet.

Samsung, Stanford Built a 10,000 PPI Display That Could Revolutionize VR, AR

Ask anyone who has spent more than a few minutes inside a VR headset, and they'll mention the screen door effect. This could eliminate it for good.